1. Lam CSP, Harding E, Bains M, et al. Identification of urgent gaps in public and policymaker knowledge of heart failure: results of a global survey. BMC Public Health. 2023;23(1):1023. doi:10.1186/s12889-023-15405-4
2. Bozkurt B, Ahmad T, Alexander KM, et al. Heart failure epidemiology and outcomes statistics: a report of the heart failure Society of America. J Card Fail. 2023;29(10):1412-1451. doi:10.1016/j.cardfail.2023.07.006
3. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7-11. doi:10.15420/cfr.2016:25:2
4. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi:10.1056/NEJMoa1504720
5. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. doi:10.1056/NEJMoa1611925
6. Saisho Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes? Diseases. 2020;8(2):14. doi:10.3390/diseases8020014
7. Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med. 2021;8:777861. doi:10.3389/fmed.2021.777861
8. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in non-diabetic patients with HFrEF (EMPA-TROPISM). J Am Coll Cardiol. 2021;9(8):578-589. doi:10.1016/j.jchf.2021.04.014
9. Murashima M, Tanaka T, Kasugai T, et al. SGLT2 inhibitors and anemia among diabetes patients in clinical practice. J Diabetes Investig. 2022; 13(4):638-646. doi:10.1111/jdi.13717
10. Kanbay M, Tapoi L, Ureche C, et al. Effect of SGLT2 inhibitors on hemoglobin and hematocrit in type 2 diabetes: meta-analysis. Int Urol Nephrol. 2022;54(4):827-841. doi:10.1007/s11255-021-02943-2
11. McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF trial. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303
12. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190
13. Zannad F, Ferreira JP, Pocock SJ, et al. Meta-analysis of EMPEROR-reduced and DAPA-HF. Lancet. 2020;396(10254):819-829. doi:10.1016/S0140-6736(20)31824-9
14. Nassif ME, Windsor SL, Tang F, et al. DEFINE-HF trial. Circulation. 2019;140(18):1463-1476. doi:10.1161/CIRCULATIONAHA.119.042929
15. Anker SD, Butler J, Filippatos G, et al; EMPEROR-preserved trial investigators. Empagliflozin in HFpEF. N Engl J Med. 2021;385(16):1451-1461. doi:10.1161/CIRCULATIONAHA.121.056824
16. Solomon SD, McMurray JJV, Claggett B, et al; DELIVER trial investigators. Dapagliflozin in HFpEF. N Engl J Med. 2022;387:1089-1098.
17. Nassif ME. Dapagliflozin in HFpEF: randomized trial (DEFINE-Preserved). JAMA. 2021;326:1959-1969.
18. Kosiborod MN. PRESERVED-HF trial. Circulation. 2021;144:1353-1365.
19. Borlaug BA. EMPERIAL-Preserved trial. Eur Heart J. 2020;41:2601-2612.
20. Jaiswal A, Jaiswal V, Ang SP, et al. SGLT2 inhibitors in HFpEF: meta-analysis. Medicine (Baltimore). 2023;102(39):e34693. doi:10.1097/MD. 0000000000034693
21. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC HF Guidelines. Eur Heart J. 2021;42(42):3599-3726. doi:10.1093/eurheartj/ehab670
22. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA HF Guidelines. Circulation. 2022;145:e895-1032.
23. Maddox TM, Januzzi JL, Allen LA, et al. 2024 ACC consensus pathway for HFrEF. J Am Coll Cardiol. 2024;83(15):1444-1488. doi:10.1016/j.jacc. 2023.12.024
24. Mebazaa A. STRONG-HF trial. Lancet. 2022;400:1757-1769.
25. Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT2 inhibitors: safety review of real-world data and randomized clinical trials. Curr Probl Cardiol. 2024; 49(9):102664. doi:10.1016/j.cpcardiol.2024.102664
26. Buse JB, Wexler DJ, Tsapas A, et al. ADA-EASD consensus report. Diabetes Care. 2020;43(2):487-493. doi:10.2337/dci19-0066
27. Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463-1476. doi:10.1016/j.ekir. 2022.04.094
28. von Lewinski D, Kolesnik E, Tripolt NJ, et al. EMMY trial. Eur Heart J. 2022;43(41):4421-4432. doi:10.1093/eurheartj/ehac494
29. Luo J, Feldman R, Callaway Kim K, et al. Evaluation of out-of-pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 RA in patients with type 2 diabetes and cardiovascular disease. JAMA Netw Open. 2023;6(6):e2317886. doi:10.1001/jamanetworkopen.2023. 17886
30. McEwan P, Foos V, Martin B, Chen J, Evans M. Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence. Diabetes Obes Metab. 2023;25(7):1830-1838. doi:10.1111/dom.15040